// App-Quantinova.ai

P142 : KEYNOTE-013: an open-label, multicohort phase Ib trial of pembrolizumab in patients with advanced hematologic malignancies

Researchers

Presenter

  • Philippe Armand

Principal Investigators

  • John Kuruvilla

  • Craig Moskowitz

  • Mehdi Hamadani

  • Vincent Ribrag

  • Pier Luigi Zinzani

  • Sabine Chlosta

  • Seth Thompson

  • Arun Balakumaran

  • Nancy Bartlett

Medical Centers

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Institut Gustave Roussy, Villejuif, Ile-de-France, France

  • Institute of Hematology, University of Bologna, Bologna, Italy

Locations

  • France

  • Canada

  • Italy

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hematological malignancies

  • Alpha-thalassemia myelodysplasia syndrome

  • Non-Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Follicular lymphoma

  • Hodgkin's Lymphoma

  • B cell lymphomas

  • Diffuse large B-cell lymphoma

  • Lymphomas

Biomarkers

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Pembrolizumab

  • Lenalidomide

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved